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Simultaneous speciation of arsenic and selenium in human urine by
high-performance liquid chromatography inductively coupled plasma
mass spectrometryw
Fumin Pan, Julian F. Tyson and Peter C. Uden
A procedure for the simultaneous determination of six selenium species and six arsenic species in
human urine by ion-pair, reversed-phase liquid chromatography coupled to ICP-MS has been
developed. Selenium species, trimethylselenonium ion (TMSe), selenocystine (SeCys), selenite
(SeIV), selenourea (SeUr), selenomethionine (SeMet), selenoethionine (SeEt), and arsenic species,
arsenocholine (AsC), arsenobetaine (AsB), dimethylarsinic acid (DMA), methylarsonic acid
(MMA), arsenite (AsIII), arsenate (AsV) were separated on a C8 reversed phase column by a
mobile phase of 13.0 mmol l1 tetrabutylammonium hydroxide (ion-pair reagent) and 1.3%
methanol at pH 5.7–5.8 (adjusted with malonic acid). The total analysis took less than 10 min
with isocratic elution at a flow rate of 1.0 ml min1, and was free from chloride interference due
to the complete separation of the analyte species from chloride. The detection limits, in synthetic
urine for an injection volume of 50 mL, ranged between 0.1 and 0.4 mg l1 for the six arsenic
species (except AsC) and between 0.7 and 2 mg l1 for the six selenium species (at m/z 78). The
repeatability was less than 10% (RSD) for 1 mg l1 arsenic species and 5 mg l1 selenium species,
except for AsC. Quantification was based on response factors in a synthetic urine matrix relative
that of AsV in the mobile phase. The response factors for selenium species showed considerable
compound dependence. Recoveries from spiked urine samples ranged from 81% to 103%, except
for SeUr and SeEt, which were not recovered. The method was applied to the determination of
arsenic and selenium species in urine, which only required filtering through a 0.45 mm membrane
filter and dilution with mobile phase in order to measure arsenic and selenium urinary
metabolites.
Introduction
Arsenic is widespread in nature and is drawing increasing
attention due to its high toxicity and water source contamina-
tion in several parts of the world.1 Chronic arsenic exposure
may increase the risk of skin, lung, and bladder cancers or
damage the immune and cardiovascular systems.2 It is well
known that the toxicity of arsenic depends on its chemical
form, and inorganic arsenic species, arsenite and arsenate, are
believed to be more toxic than organic species. However,
recent studies show that the methylated trivalent arsenic
species found in human urine3 may be more toxic than
inorganic arsenic.4,5 Human exposure normally occurs
through consumption of arsenic-containing food and drink,
whose arsenic content varies from o0.1 to 25 mg g1.6 After
metabolism, inorganic arsenic species, which have been methy-
lated, are excreted in urine as DMA and MMA, while organic
arsenic species such as AsB and AsC are excreted unchanged.7
Within a small intake window, selenium plays an important
biological role in human health. It is an essential element that
also has cancer prevention properties.8 Selenium is present at
the active site of glutathione peroxidase and acts as a redox
center to protect cells from oxidation damage.9 Selenium
deficiency has been linked to some diseases in countries such
as China;10 DNA damage by the generation of reactive oxygen
species could arise from excess selenium.11 The multiple roles
of selenium depend on its chemical form and concentration.
Foods provide mainly organoselenium compounds such as
selenomethionine, selenocysteine and Se-methylselenocys-
teine, while most supplements contain selenomethionine
bound in selenized yeast and sometimes selenate or selenite.
Urine is a major excretion route for consumed selenium.12
Francesconi and Pannier13 reviewed the previous studies of
urinary metabolites and concluded that selenosugars should be
considered to be the major urinary selenium species (rather
than the trimethylselenonium ion), while for other com-
pounds, such as selenomethionine and selenocystine, more
evidence is needed if they are to be accepted as typical urine
metabolites.
There is evidence that arsenic and selenium species can
interact in biological systems and cause mutual detoxifica-
tion.14 Moxon first reported the antagonism between arsenic
and selenium when he observed that arsenite in drinking water
could protect animals from selenium toxicity.15 One solid
proof of interaction is the identification of the As–Se
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compound seleno-bis(S-glutathionyl)arsonium ion, [(GS)2AsSe]
,
in bile excretion.16 The proposed mechanisms of the antag-
onistic interactions between As and Se, including direct as well
as metabolic interactions, have been reviewed by Zeng et al.14
Urinary arsenic and selenium are known to be highly
correlated with recent arsenic and selenium intake.17,18 The
chemical forms and quantities of urinary arsenic and selenium
are useful indicators to probe the status, the interactions and
the possible metabolic pathways of arsenic and selenium in the
body. Techniques for the simultaneous speciation of arsenic
and selenium are needed to support such studies.
Commonly used element-specific detection techniques, such
as atomic absorption spectrometry (AAS), atomic fluorescence
spectrometry (AFS), inductively coupled plasma atomic emis-
sion spectrometry (ICP-AES) and inductively coupled plasma
mass spectrometry (ICP-MS) can be coupled to HPLC. As a
robust and sensitive combination, HPLC-ICP-MS provides a
powerful technique for the determination arsenic and sele-
nium.19
Ion-exchange and ion-pair, reversed-phase chromato-
graphic methods have been widely used for separating arsenic
and selenium compounds in biological materials including
urine.20,21 Arsenic species have been mostly separated by
ion-exchange, while selenium species have been mostly sepa-
rated by ion-pairing, reversed-phase procedures.22 Eight ar-
senic compounds, AsIII, AsV, DMAIII, DMAV, MMAIII,
MMAV, AsB and AsC were separated on both anion- and
cation-exchange columns.23 Separation of anionic, cationic
and neutral selenium species, namely SeVI, SeUr, SeMet, SeEt
and TMSe+, was achieved on a reversed-phase column with
sodium 1-butanesulfonate and tetrabutylammonium hydro-
xide as ion-pair reagents.24 Only a limited number of the
separation systems have been reported for the simultaneous
speciation of arsenic and selenium. Orero Iserte et al. devised
an anion-exchange separation of AsIII, AsV, DMA, MMA,
SeIV and SeVI on a Hamilton PRP-X100 column with an
NH4H2PO4 mobile phase,
25 and applied the method to the
analysis of sediment extracts. Do et al. separated ten arsenic
and selenium species, mainly found in the environment and in
mammals, on a reversed-phase column, with tetrabutylammo-
nium phosphate as the counter-ion.26 The separated species
were collected in 75 ml fractions and quantified by ETAAS.
The retention time of chloride, a key interferent if ICP-MS
detection were to be used, was not investigated. Le et al.
achieved baseline separation of thirteen inorganic and organic
arsenic and selenium species on a reversed-phase column with
hexanesulfonate as the ion-pair reagent;27 however, for urine
analysis they used a different column and a different mobile
phase, though elevated temperatures were still needed (70 1C)
to decrease the separation time from 37 to 18 min.
We have developed an ion-pair, reversed-phase, C8 HPLC
procedure with ICP-MS detection for the simultaneous deter-
mination of six arsenic species, AsC, AsB, DMA, MMA, AsIII,
AsV, and six selenium species, TMSe, SeCys, SeIV, SeUr,
SeMet, and SeEt, in human urine within 10 min. The isocratic
separation is at room temperature, with detection of selenium
at m/z 78 and arsenic at m/z 75, for which the chloride
interference was removed by chromatographic separation.
The method was developed to study possible interactions
between arsenic and selenium metabolism as evidenced by
urinary temporal profiles of compounds containing these
elements following ingestion of seafood and/or a selenium
supplement. Urine samples were analyzed following filtering
and dilution with mobile phase.
Experimental
Instrumentation
The chromatographic system consisted of a Spectra Physics
Model 8810 precision isocratic pump (San Jose, CA, USA), a
Rheodyne Model 7010 sample injector (Rohnert Park, CA,
USA) equipped with a 50 mL sample loop and a Waters
Symmetry C8 reversed-phase column 250 mm  4.6 mm id,
containing 5 mm particles (Milford, MA, USA). The chroma-
tographic eluent (1.0 ml min1) was coupled directly to the
cross-flow nebulizer and the Scott-type, double-pass spray
chamber of the spectrometer. The ICP-MS instrument was a
PerkinElmer Model Elan 6100 DRC-e (Norwalk, CT, USA).
The operating parameters are summarized in Table 1. To
achieve the best sensitivity, the ICP-MS conditions indicated
in Table 1 were tuned daily by aspirating a standard solution
of 10 mg l1 of In, Mg, Pb, Ce, and Ba. Ion intensities at m/z
75, 78, 82 were recorded with the PE Elan time-resolved
analysis software. Quantification was performed in the peak
area mode using OriginPro7.5 (OriginLab, USA). The pH was
measured with an Accumet 915 pH meter Fisher (Fairlawn,
NJ, USA) which was calibrated daily using pH 4.0 and pH 7.0
standard solutions.
Reagents
All chemicals were of analytical grade and were used without
further purification. High-purity water was produced by an
E-pure Deionized Water System (Barnstead, Dubuque, IA,
USA). Selenomethionine, selenocystine, selenoethionine, sele-
nourea, sodium selenate, sodium selenite and arsenobetaine
Table 1 Operating conditions for HPLC and ICP-MS instruments
HPLC
Column Waters Symmetry C8 (250  4.6 mm id,
5 mm particle size)
Mobile phase 13.0 mmol l1 tetrabutylammonium
hydroxide
1.3% methanol pH 5.7–5.8 adjusted with
malonic acid
Flow rate 1.0 ml min1
Injection volume 50 ml
Column temperature Ambient
ICP-MS
Rf power 1125 W
Plasma Ar flow 15.00 l min1
Auxiliary Ar flow 1.18 l min1
Nebulizer Ar flow 0.90 l min1
Lens voltage 8.60 V
Data acquisition mode Time resolved analysis




Isotopes monitored 75As, 78Se, 82Se
were purchased from Sigma (St. Louis, MO, USA), trimethyl-
selenonium iodide from Organometallics Inc. (East
Hampstead, NH, USA), sodium arsenite and sodium
arsenate from Fisher, monomethylarsonic acid (MMA)
from ChemService Inc. (West Chester, PA, USA), and
dimethylarsinic acid (DMA) from Pfaltz & Bauer (Waterbury,
CT, USA). Arsenocholine was provided by Dr X.-C. Le
of the University of Alberta. Stock 1000 mg l1 (as Se
or As) solutions were prepared in 10.0 ml of deionized water
and stored in a freezer at 20 1C. Working standard solutions
in the mg l1 range were prepared daily by appropriate
dilution.
Tetrabutylammonium hydroxide (TBAH) obtained, as a 1.0
mol l1 solution in methanol, from Aldrich (St Louis, MO,
USA), was diluted as needed to prepare various mobile phase
compositions, the pH of which was adjusted by the addition of
1.0 mol l1 malonic acid (Eastman, Rochester, NY, USA) or
20% NH4OH (EMD, Gibbstown, NJ, USA). Synthetic urine,
prepared according to the procedure of Gammelgaard et al.,28
contained 55 mmol l1 of sodium chloride, 67 mmol l1 of
potassium chloride, 2.6 mmol l1 of calcium sulfate, 3.2 mmol
l1 of magnesium sulfate, 19.8 mmol l1 of sodium dihydrogen
sulfate, 29.6 mmol l1 of sodium sulfate, 310 mmol l1 of urea
and 9.8 mmol l1 of creatinine in deionized water. These
reagents were all purchased from Fisher, except magnesium
sulfate (Mallinckrodt), creatinine (Sigma) and urea (EMD).
The selenium supplement (Schiff Products, Salt Lake City,
UT, USA) was purchased from a local supermarket. This
material consists of tablets, each of which contains 200 mg of
selenium (as Se), a value that has been verified.29 It is also
known that in this material about 80% of the selenium is
present as selenomethionine (or the corresponding selenox-
ide).30 The pollock seafood (Matlaws, National Fish & Sea-
food Inc., Gloucester, MA, USA) was bought from a local
supermarket and stored at 20 1C. This material contained
0.29 mg kg1 of arsenic (as As).31
Urine samples
Urine contains high concentrations of urea, proteins, sodium
and potassium,32 which often cause matrix interference effects.
Several procedures have been proposed to minimize these
interferences, such as C18 solid-phase extraction to remove
the organic matrix,33 crown ether extraction to remove potas-
sium and sodium,34 methanol extraction for de-salting,35 and
ethanolic precipitation for de-salting and de-proteinization.36
Another difficulty is the low analyte concentrations, which has
led to attempts to preconcentrate prior to speciation.37 These
various clean-up and concentration procedures have brought
other problems, such as the oxidation of selenosugars,37 the
loss of inorganic selenium,38 the oxidation of monomethylated
selenium39 and the degradation of selenosugars,35 all of which
affect the accuracy and precision of the quantification. These
results indicate that the sample treatment should be as simple
as possible, involving only filtration and dilution and that
speciation analysis should be carried out with fresh samples.
Therefore, it was decided only to filter the urine samples
through a 0.45 mm filter and dilute them (1 + 4) with mobile
phase on the day of analysis.
Urine samples were collected in the morning, afternoon and
evening from a male volunteer and mixed for the recovery tests
in which 5 mg l1 of arsenic species and 10 mg l1 of selenium
species were added. Urine samples were collected 11 h after
consumption of a selenium dietary supplement and/or sea-
food, stored in polyethylene sample containers at 4 1C and
analyzed within one week. Prior to analysis, urine samples
were filtered through a 0.45 mm filter (Whatman, Florham
Park, NJ) and diluted (1 + 4) with mobile phase.
Method development and validation
Optimization. The retention characteristics of the arsenic
and selenium species were considered to be mainly determined
by their hydrophobic nature and their charge. Therefore, both
the concentration of the ion-pairing reagent, tetrabutylammo-
nium hydroxide (TBAH), and the pH could influence the
separation. The pH was adjusted with malonic acid, as re-
ported by Zheng et al.24 The concentration of TBAH, mobile
phase pH value and injection volume were optimized in this
study to get baseline separations with good peak shapes for
both the arsenic and the selenium species. The concentration
of methanol was kept at the minimum value that arose from
the dilution of the stock TBAH solution, which was supplied
dissolved in methanol. The cyclic alternating variable search
strategy was adopted in line with our previous approaches to
complex optimizations.40 In this procedure, each variable is
changed in turn, while the others are held constant, until a
maximum in the response factor (or figure of merit) space has
been found. The process is then repeated for a second and,
possibly, a third time. This has the advantage over a procedure
in which more than one variable is changed simultaneously
that at the conclusion of the process, the shape of the factor
space is known as a function of each of the parameters. The
concentration of ion-pairing reagent was varied from 5 mmol
l1 to 13 mmol l1, initially at pH 6.0, and the pH was varied
from 5.0 to 7.0. In order to achieve higher sensitivity and lower
detection limits, a large injection volume is preferred. How-
ever, increasing the sample volume will decrease separation
efficiencies, by increasing peak broadening and/or producing
peak overlap. Sample volumes of 20, 50, or 100 ml were
injected.
It is well known that the argon dimers 40Ar2
+ and 40Ar38Ar
interfere with the major isotope of selenium at m/z 80 (49.6%)
and 78 (23.8%). The dynamic reaction cell (DRC) has usually
been used to minimize the background caused by the argon
dimers. However, it was observed that the sensitivities for both
the 75As and the 78Se signals were decreased (up to 50-fold in
some cases) by reaction with methane in the DRC. Without a
DRC, the background signal at m/z 78 was constant through-
out the chromatographic run at 15 000 cps; with the DRC, the
background was about 300 cps. As the standard deviation of
the signal equals its square root, it may be estimated that a
lower signal to noise ratio (and hence limit of detection) is
obtained under the higher sensitivity conditions.
In the study of human urine, the molecular ions 40Ar37Cl+,
12C35Cl2
+ and 40Ar35Cl+ strongly interfere with the 77Se, 82Se
and 75As isotopes, respectively. The average Cl concentration
in human urine may be as high as 5 mg ml1,41 which after a
5-times dilution would be decreased to about 1 mg ml1. To
evaluate the effect of Cl on the chromatographic separation,
arsenic and selenium standards prepared with the presence of 1
mg ml1 Cl (as NaCl) were injected into the HPLC-ICP-MS
system. A solution containing only 1 mg ml1 Cl (as NaCl)
was also injected.
Analytical performance. To characterize the performance of
the method, the following figures of merit were evaluated: (a)
calibration range (solutions covering the concentration range
of 0–100 mg l1 in both mobile phase and synthetic urine
matrices were injected), (b) limit of detection (defined as the
concentration giving a signal equal to 3 times the standard
deviation of the peak area, for n = 6, of 1 mg l1 As and 5 mg
l1 Se in both mobile phase and synthetic urine matrices), and
(c) precision (expressed as the RSD of 6 injections of 1 mg l1
arsenic species and 5 mg l1 selenium species in either mobile
phase or synthetic urine).
For quantification, peak area response factors for each
species relative to the response for AsV in the mobile phase
were calculated for both mobile phase and synthetic urine
matrices. The factors were calculated for the injection of the
same concentration of the element for each of the 12 species.
The concentrations included 1, 5, 10, 50, and 100 mg l1 for the
arsenic species and 5, 10, 50, and 100 mg l1 for the selenium
species. The response factors for each species were calculated
as the average of the response factors for all concentrations.
Matrix effects were investigated by spiking arsenic (5.0 mg l1)
and selenium (10.0 mg l1) standards individually into a real




Chromatograms showing the influence of the variation of
TBAH concentration on the ion-pairing HPLC-ICP-MS chro-
matogram of arsenic and selenium standards are provided in
the Electronic Supplementary Information (ESI)w. As the
TBAH concentration was increased from 5 to 13 mmol l1,
the resolution between AsIII and AsB improved, and stabilized
for TBAH concentrations greater than 8 mmol l1, although
the peaks were still partially overlapping. All other arsenic
peaks were baseline separated over the entire range of TBAH
concentrations, though the peaks for AsC and AsB, AsIII and
DMA, DMA and MMA moved closer with increasing TBAH
concentration. Meanwhile, the total elution time for all arsenic
peaks was decreased from about 10 to 7 min. Higher TBAH
concentrations (greater then 13 mmol l1) are not recom-
mended as the resolution between some arsenic peaks caused
by the tailing of peaks for AsC, AsIII and DMA becomes
worse. The peaks for SeUr and SeMet were separated at low
TBAH concentration (less than 8 mmol l1), but with increas-
ing concentration they co-eluted and then switched elution
sequence, becoming once again baseline separated when the
TBAH was 13 mmol l1. Again, the total elution time for all
selenium species was decreased from about 11 to 9 min.
Considering both arsenic and selenium chromatograms under
the influence of TBAH concentrations, 13 mmol l1 of TBAH
was selected as the optimum concentration. The retention
times of all arsenic and selenium species were sensitive to pH
values between 5.0 and 6.0 (details shown in the ESIw). At pH
5.0, peaks for all selenium species were baseline separated, but
the peaks for AsB, AsIII and DMA were not resolved. As the
pH was increased from 5.5 to 6.0, the resolution between peaks
for AsIII and DMA was improved while the resolution be-
tween AsC and AsB, and DMA and MMA was poorer. At pH
6.0, TMSe and SeCys co-eluted. The effect of pH values
between 5.5 and 6.0 on the resolutions of those peaks was
further investigated. It was found that at pH 5.7–5.8, the
overlap between TMSe and SeCys, and between AsIII and
DMA, were minimized, and this value was chosen. The effect
of changing sample injection volume on the retention times
and peak shapes of arsenic and selenium compounds for the
optimum TBAH concentration and pH value are also shown
in the ESIw. Resolutions were not affected for injection
volumes of 20 and 50 ml, and so the larger volume was selected.
The optimized chromatographic conditions are shown in
Table 1. As can be seen from Fig. 1, baseline separations of all
Fig. 1 Chromatograms of standard solution in the mobile phase
containing six arsenic compounds, and six selenium compounds (10 mg
l1) and 1000 mg ml1 Cl (as NaCl). Peak identification: 1, AsC; 2,
AsB; 3, AsIII; 4, DMA; 5,MMA; 6, AsV; 7, TMSe; 8, SeCys; 9, SeMet;
10, SeUr; 11, SeIV; 12, SeEt; and 13 Cl.
peaks, except for those of AsB and AsIII, within 10 min were
obtained. Although selenate was originally included in the
compounds studied, it was not included in the compounds
determined in the urine samples as there are no definitive data
demonstrating that selenate is a typical constituent of urine.13
The retention time for selenate is about 40 min. The addition
of chloride had no effect on the selenium chromatograms, but
was visible as a late eluting broad peak in the arsenic chro-
matograms that was well separated from the final AsV peak.
The chromatogram shown in Fig. 1(c) shows the signal at m/z
35 which includes a significant contribution from chlorine. A
better signal to noise ratio was obtained for selenium at m/z 78
and measurements were made at this rather than at m/z 82.
Analytical performance
The calibration curves for the six arsenic and six selenium
standards were linear over the range of 0–100 mg l1 in both
mobile phase and synthetic urine matrices with correlation
coefficients all greater than 0.995. The relative response factors
are shown in Table 2. These values show some interesting
variations, suggesting that the ICP-MS response is not com-
pound-independent. As the purity of the AsC material is not
known (though it is not accompanied by any other arsenic-
containing compounds), it is possible that the low value for
this species is due to inaccuracy in the calculated concentra-
tion. The effect would appear to be more pronounced for the
selenium species. The values normalized to the value for
selenite are also shown in Table 2, from which it can be seen
that the response for selenium compounds in which the
selenium is bound to carbon are significantly lower than the
response for the oxoanion SeO3
2. To our knowledge, the
issue of compound dependency in quantitative speciation with
ICP-MS detection has not been reported previously, although
differences for the ICP-OES responses of arsenite and arsenate
have been observed,42 but not definitively explained. This
phenomenon, which we have also observed with ICP-OES
and selenium compounds, is the subject of further study.29 Our
current hypothesis is that the differences in sensitivity arise
from differences in atomization efficiencies, and hence ioniza-
tion efficiencies, within the central channel of the plasma, i.e.,
the different compounds give rise to a variety of molecular
species (such as hydrides, alkyls, carbonyls and oxides) due to
incomplete atomization during the residence time in the
plasma.
The spike recoveries from a real urine sample for arsenic
(5.0 mg l1) and selenium (10.0 mg l1) are also shown in Table
2. The values ranged from 81% to 103% except for those for
SeUr and SeEt, whose signals were completely suppressed by
the urine matrix. Generally, the recovery values for the arsenic
species were higher than those of the selenium species.
The detection limits, summarized in Table 3, ranged from
0.09 to 0.2 mg l1 (for arsenic species) and 0.5 to 1 mg l1 (for
selenium species) for the mobile phase matrix, and from 0.1 to
0.4 mg l1 (for arsenic species) and 0.7 to 2 mg l1 (for selenium
species) for a synthetic urine matrix. These values are suitable
for the direct speciation of arsenic and selenium in human
urine samples, according to the reported concentrations of
arsenic and selenium in urine, and are comparable to pre-
viously reported values.24,43,44 The repeatabilities, also shown
in Table 3, were less than 10%RSD for 1 mg l1 arsenic species
and 5 mg l1 selenium species spiked in both the mobile phase
and a synthetic urine matrix, except for AsC, the RSD of
which was 15%.
Peak identification
The chromatograms of a urine sample collected 11 h after
seafood consumption and the same urine sample spiked with
individual arsenic standards are shown in Fig. 2. A total of 7
arsenic-containing peaks can be seen. Of these, six could be
identified by retention time matching, with one minor un-
known peak just before 6 min. In agreement with previously
reported distributions,41 the major urinary arsenic species was
DMA. Hulle et al.20 investigated the unknown species present
in ion-exchange chromatograms of urine samples after inges-
tion of food containing arsenosugars, and concluded that the
arsenosugars were completely transformed into DMA, MMA
and unknown metabolites. Therefore, the unknown peak in
Fig. 2 is assigned as an arsenosugar metabolite. As can be seen
from Fig. 3(a), the only selenium species that could be
identified in urine collected 11 h after 1.0 mg selenium
supplementation was TMSe+, though this was not the major
species. Two minor unknown species, unknown 1 (with a
retention time of 3.8 min) and unknown 2 (with a retention
time of 5.1 min) were also found. The major species, with a
Table 2 Response factors and recovery
Species
Response factors relative to AsV
Relative to SeIV Recoverya (%)Mobile phase Synthetic urine Average RSD (%)
AsC 0.699 0.783 0.741 5.8 85  11
AsB 1.25 1.32 1.28 3.2 97  5
AsIII 1.02 1.04 1.03 4.7 96  4
DMA 1.12 1.20 1.16 6.4 98  3
MMA 0.955 1.02 0.989 2.6 94  6
AsV 1.00 1.02 1.01 4.6 101  4
TMSe 0.279 0.272 0.276 5.3 0.701 81  2
SeCys 0.252 0.303 0.278 4.9 0.706 100  9
SeMet 0.297 0.322 0.310 5.4 0.786 84  6
SeUr 0.321 0.243 0.282 10 0.716 0
SeIV 0.374 0.413 0.394 12 1.00 103  4
SeEt 0.253 0.214 0.233 7.0 0.591 0
a The  terms are 95% confidence intervals, n = 3.
retention time of 6.1 min, is seen in Fig. 3(b), which is a
continuation of the chromatogram with an expanded time
scale and a compressed response scale. The peak for this major
species partially overlapped that for the spiked SeIV to form a
broad peak. Franscesconi and Pannier have presented13 a
thorough evaluation of the literature relating to selenium
speciation in urine (both rat and human) and concluded that
methyl 2-acetamido-2-deoxy-1-seleno-b-D-galactopyranoside
is ‘‘firmly established’’ as the ‘‘major selenium metabolite after
supplementation with . . . selenized yeast’’ in urine. Recent
results45 for separation on a 150 mm  4.6 mm C18 reversed-
phase HPLC column with ICP-MS detection showed this
major metabolite eluting between 7 and 8 min, with a mobile
phase flow rate of 1.0 ml min1. Therefore, the largest peak (at
6.1 min) shown in Fig. 3(b) is assigned to this selenosugar.
This major species was detected in all urine samples collected
2, 4, 6, 9, 11, 13, 21 and 25 h after ingestion of a 1.0 mg
selenium supplement.31 In agreement with the results of
recently published studies, TMSe was not the major selenium
metabolite, though it was detectable. This is in contrast to the
findings of Gammelgaard and Bendahl,46 who did not detect
TMSe (o0.5 mg l1) in urine even after supplementation with
2 mg of selenium as selenized yeast. It should be noted that in
ref. 13, Franscesconi and Pannier refer to methyl 2-acetamido-
2-deoxy-1-seleno-b-D-galactopyranoside as ‘‘selenosugar 2’’,
whereas in the later paper,45 this compound is labelled ‘‘sele-
nosugar 1’’. Gammelgaard and co-workers,46,47 who refer to
this compound as Se-methyl-N-acetylgalactosamine, also con-
sider that it is the major metabolite in urine after supplemen-
tation with selenized yeast. The small peak just before three
minutes is possibly also a selenosugar, as this would be
consistent with previous results45 in which methyl 2-amino-
2-deoxy-1-seleno-b-D-galactopyranoside was shown to elute
at around 3 min under the conditions for which methyl
2-acetamido-2-deoxy-1-seleno-b-D-galactopyranoside eluted
at about 7 min.
Conclusions
It is possible to separate six arsenic species (AsC, AsB, MMA,
DMA, AsIII, AsV) and six selenium species (SeIV, SeCys,
TMSe, SeEt, SeMet, SeUr) in urine in less than 10 min by a
method based on a reversed-phase ion-pair chromatography,
at room temperature, with isocratic elution, coupled with ICP-
MS detection down to concentrations of between 0.1 and 1 mg
l1. The procedure is free from Cl interference, as chloride
Table 3 Detection limit and repeatability for 1 mg l1 (As) and 5 mg
l1 (Se ) spiked mobile phase or synthetic urine. (n = 6)
Species
Repeatability, RSD (%) Detection limita/mg l1
Mobile phase Synthetic urine Mobile phase Synthetic urine
AsC 5.1 14 0.15 0.43
AsB 5.3 6.4 0.16 0.19
AsIII 3.1 5.0 0.09 0.15
DMA 5.6 3.3 0.17 0.10
MMA 5.1 5.3 0.15 0.16
AsV 3.2 4.0 0.10 0.12
TMSe 9.3 8.4 1.4 1.3
SeCys 4.0 4.7 0.60 0.71
SeMet 3.4 6.7 0.51 1.0
SeUr 7.5 10 1.1 1.5
SeIV 4.7 8.3 0.71 1.3
SeEt 5.5 6.7 0.83 1.0
a Second digit shown for information.
Fig. 2 Chromatograms of a urine sample (collected 11 h after seafood
consumption, continuous line) and the same urine sample spiked with
5 mg l1 (as As) of six arsenic species (broken line). Peak identification:
1, AsC; 2, AsB; 3, AsIII; 4, DMA; 5,MMA; 6, AsV; 7, unknown.
Fig. 3 Chromatograms of a urine sample (collected 11 h after 1.0 mg
selenium supplementation, continuous line) and the same urine sample
spiked with 10 mg l1 (as Se) of (a) four selenium species, respectively
(broken line), (b) SeIV (broken line). Peak identification: 1, TMSe;
2, SeCys; 3, SeMet; 4, unknown 1; 5, unknown 2; 6, SeIV/methyl
2-acetamido-2-deoxy-1-seleno-b-D-galactopyranoside.
elutes after all of the arsenic (and selenium) species of interest
have eluted, and requires only minimal sample pre-treatment.
Quantification in a real urine matrix, based on response
factors relative to the response for AsV, would be possible
for all species except SeUr and SeEt. Significant differences in
response factors for selenium compounds were observed,
which is the subject of on-going further study. The method
is suitable for application to a study of the urinary excretion
and metabolite distribution of arsenic and selenium when
ingested simultaneously and separately. Such a study would
provide further information about the interactions between
arsenic and selenium in human metabolism.31
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